Predict your next investment

Venture Capital
scppartners.com

See what CB Insights has to offer

Investments

57

Portfolio Exits

17

Funds

2

About SCP Partners

SCP Partners is a diversified mulit-stage venture capital firm that is focused on investments in Information and Communications Technology (ICT), Life Sciences, Services, and Defense and Security. SCP supports its investment portfolio with a rich base of strategic, operating and financial expertise and an extensive network to access capital, recruit management, and facilitate favorable strategic alliances.

SCP Partners Headquarters Location

1200 Liberty Ridge Drive Suite 300

Wayne, Pennsylvania, 19087,

United States

610-995-2900

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest SCP Partners News

Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Partners Ltd

Dec 23, 2019

| Source: Oncology Pharma, Inc. SAN FRANCISCO, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to facilitate a financing of US$ 38.4 Million from SCP Partners, Ltd, UK. Financing is to be used to complete licensing agreements with Kalos Therapeutics for its lead anti-cancer bio-pharmaceutical (a peptide) medication, KTH-222. Kalos’ platform of peptide-based therapeutic drugs have internationally issued patents (EP 2 224 946 B1), along with a number of international patents pending. Also included in the financing is the completion of the licensing agreement with Ribera Solutions for its Connect2Med Application. Subject to a 90 day due diligence period. Oncology Pharma previously announced the execution of a Letter of Intent with Diagnomics, Inc. to acquire a 50% interest. As part of the transaction, Onco Pharma will acquire a 5% interest of India-Eone Diagnomics center and also include a 3.25% stake in Eone Diagnomics of South Korea. Eone Diagnomics was one of the most successful biotech IPOs on the KOSDAQ in 2018 attaining a high value of US$ 250M in that year. Diagnomics is a CLIA and a CAP accredited laboratory in San Diego, CA. The company provides CLIA services to global pharmaceutical companies, including academic and biotech companies. Diagnomics' artificial intelligence combined with artificial intelligence is a "game changer" in precision medicine, drug development, clinical trials, lowering of cost and time of clinical trials, faster regulatory approval process and faster availability of drugs to the patients. According to Coherent Market Insights, the global oncology drugs market was valued at US$ 77.3 billion in 2018 and is projected to exhibit a CAGR (Compound Annual Growth Rate) of 12.3% through 2026. In light of our LOI with Diagnomics, Inc. the global Genomic Market is valued at US$ 13.2 Billion and expected to grow to US$ 30.59 Billion by 2025 at a CAGR of 9.78% according to Kenneth Research Oncology Pharma CEO, Chuck Wagner, commented: “I am delighted to have received a Letter of Intent to facilitate the necessary financing for Oncology Pharma to execute our business plan and taking this step to completing our acquisitions and licensing agreements as previously announced.” ABOUT ONCOLOGY PHARMA, INC. ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") the Company is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare. ABOUT Diagnomics, Inc. Established in 2011, Diagnomics is one of the first Next Generation Sequencing (NGS)-based genomics companies located in California. Diagnomics’ mission is to provide sophisticated solutions for personalized medicine and next generation healthcare. Diagnomics offers high-quality innovative R&D and CLIA services to global pharmaceutical, biotech, and medical device companies as well as academic institutions. Diagnomics provides comprehensive consumer genomic solutions based on several platforms including but not limited to DNA microarrays, Next Generation Sequencing and real-time PCR. FORWARD LOOKING STATEMENTS Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. CONTACTS:For additional information, please contact the Oncology Pharma at:One Sansome Street, Suite 3500San Francisco, CA 94104Phone: 415-869-1038Fax: 415-946-8801Email: info@oncology-pharma.com Related Articles

SCP Partners Investments

57 Investments

SCP Partners has made 57 investments. Their latest investment was in Magnolia Broadband as part of their Series F - II on July 7, 2013.

CBI Logo

SCP Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/9/2013

Series F - II

Magnolia Broadband

$3M

No

3

2/23/2010

Series B - II

Echo360

$6.8M

No

8/11/2009

Series F

Magnolia Broadband

$3.4M

No

8/8/2009

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/21/2008

Series B

Subscribe to see more

$99M

Subscribe to see more

0

Date

7/9/2013

2/23/2010

8/11/2009

8/8/2009

10/21/2008

Round

Series F - II

Series B - II

Series F

Series A

Series B

Company

Magnolia Broadband

Echo360

Magnolia Broadband

Subscribe to see more

Subscribe to see more

Amount

$3M

$6.8M

$3.4M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

0

SCP Partners Portfolio Exits

17 Portfolio Exits

SCP Partners has 17 portfolio exits. Their latest portfolio exit was Tammac Holdings on March 19, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/19/2019

Corporate Majority

$99M

2

10/18/2016

Acquired

$99M

3

10/22/2010

Acq - Fin

$99M

8/9/2010

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/11/2008

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

3/19/2019

10/18/2016

10/22/2010

8/9/2010

12/11/2008

Exit

Corporate Majority

Acquired

Acq - Fin

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

3

10

0

SCP Partners Acquisitions

2 Acquisitions

SCP Partners acquired 2 companies. Their latest acquisition was Wyndham Worldwide - Valley Forge Suites on September 18, 2003.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/18/2003

$99M

Acquired Unit

1

9/16/1998

Subscribe to see more

$99M

Subscribe to see more

0

Date

9/18/2003

9/16/1998

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired Unit

Subscribe to see more

Sources

1

0

SCP Partners Fund History

2 Fund Histories

SCP Partners has 2 funds, including SCP Private Equity Partners II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2001

SCP Private Equity Partners II LP

Late-Stage Venture Capital

Closed

$563M

1

12/31/1997

SCP Private Equity Partners LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2001

12/31/1997

Fund

SCP Private Equity Partners II LP

SCP Private Equity Partners LP

Fund Type

Late-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$563M

$99M

Sources

1

10

SCP Partners Team

7 Team Members

SCP Partners has 7 team members, including current Chief Financial Officer, Dennis P Ferry.

Name

Work History

Title

Status

Dennis P Ferry

Chief Financial Officer

Current

Charles Freyer

Chief Administrative Officer

Current

Winston J Churchill

Managing Partner

Current

Avi Ludomirski

General Partner

Current

Wayne B Weisman

General Partner

Current

Name

Dennis P Ferry

Charles Freyer

Winston J Churchill

Avi Ludomirski

Wayne B Weisman

Work History

Title

Chief Financial Officer

Chief Administrative Officer

Managing Partner

General Partner

General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.